The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myeloma
Lisa Leypoldt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, shares the encouraging results of the four-year follow-up of the GMMG-CONCEPT trial (NCT03104842), which investigated the isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) regimen in high-risk newly diagnosed multiple myeloma (MM). The latest data revealed an overall measurable residual disease (MRD)-negativity rate of 83.5% for transplant-eligible patients and approximately 70% for transplant-ineligible patients, translating to a long-term progression-free survival (PFS) rate of more than 50% in this high-risk patient population. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
